drugset / Trial / NCT05858632
Immune Spatial Features of Guselkumab Cutaneous Response
Phase 4
Recruiting
10 enrolled
University of California, San Francisco
Janssen Scientific Affairs, LLC · collab
NaSingle-groupOpen-labelBasic science
Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | — | — |